TTNP Profile
Titan Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for chronic diseases using its proprietary drug delivery technology. The company’s flagship technology is ProNeura, a long-term drug delivery platform designed to provide sustained release of therapeutics over extended periods. This platform underpins the company’s development of various drug products aimed at addressing significant medical needs.
Titan’s lead product is the Probuphine implant, which is approved for the maintenance treatment of opioid use disorder in clinically stable patients. This product is currently available in Canada and the European Union, offering a long-acting solution to help manage opioid addiction. The Probuphine implant leverages the ProNeura technology to provide consistent medication delivery, thereby enhancing patient compliance and treatment outcomes.
The company is advancing several other programs in its pipeline. These include the kappa opioid agonist peptide program (TP-2021), which is being developed in combination with ProNeura technology to treat chronic pruritus. Additionally, Titan is working on a nalmefene implant program designed to prevent opioid relapse following detoxification, targeting individuals recovering from opioid use disorder. Other notable initiatives include the development of a preventative therapeutic for HIV and a single ProNeura implant offering contraceptive solutions for women and adolescent girls.
Founded in 1992 and headquartered in South San Francisco, California, Titan Pharmaceuticals, Inc. continues to build on its expertise in long-term drug delivery systems. The company's innovative approach to chronic disease management and commitment to developing new therapeutic solutions underscore its role as a key player in the pharmaceutical industry. Through its ProNeura platform and diverse pipeline, Titan aims to address critical healthcare challenges and improve patient outcomes globally.
|
